Subscribe
antonio-guillem-shutterstock-com
Antonio Guillem / Shutterstock.com
7 September 2015Americas

Omeros cries foul over Par’s eye drug ANDA

Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria (phenylephrine and ketorolac injection) product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Omeros to sue Par over generic Omidria application
20 August 2015   Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria.
Americas
Sandoz agrees to drop generic in Omeros clash
30 July 2018   Sandoz has agreed to postpone its generic version of a cataract surgery drug made by biopharmaceutical company Omeros, ending a patent infringement lawsuit between the two in Delaware.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Omeros to sue Par over generic Omidria application
20 August 2015   Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria.
Americas
Sandoz agrees to drop generic in Omeros clash
30 July 2018   Sandoz has agreed to postpone its generic version of a cataract surgery drug made by biopharmaceutical company Omeros, ending a patent infringement lawsuit between the two in Delaware.

More on this story

Americas
Omeros to sue Par over generic Omidria application
20 August 2015   Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria.
Americas
Sandoz agrees to drop generic in Omeros clash
30 July 2018   Sandoz has agreed to postpone its generic version of a cataract surgery drug made by biopharmaceutical company Omeros, ending a patent infringement lawsuit between the two in Delaware.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent